QRxPharma launches the Phase 3 study Comparative safety of MoxDuo (R) IR

Study designed to evaluate the side effects and benefits of security for MoxDuo IR of Equi-analgesic Doses of Morphine and Oxycodone

(PRWeb Jan 26, 2011)

Read the full story at the http://www.prweb.com/releases/QRxPharma/MoxDuo/prweb8092601.htm

View the original article here